SC 13D/A - KINETA, INC./DE (0001445283) (Subject)

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The company will present additional scientific data in 2024 at an upcoming scientific meeting. SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the enrollment of new patients into the monotherapy arm of the VI

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, has announced that on November 8, 2024 Jason Henry M.D., Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado will be presenting the poster wi

TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the "Agreement") for Kineta's VISTA blocking antibody KVA12123. Under the terms of the A

Kineta will be trading under the symbol "KANT" on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of first offer for Kineta's KVA12123 program The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled. SEATTLE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has transitioned from Nasdaq to the OTC Market. Kineta stock now trades under the ticker symbol "KANT" on the O

30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 TAMPA, Fla. & SAN DIEGO, August 19, 2024 /PRNewswire/ -- TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Kinet

Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study 30 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 SEATTLE, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that enrollment has res

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves TuHU

TuHURA has an exclusive right to negotiate to acquire Kineta's KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States SEATTLE, July 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into an exclusivity and right of first offer agreement (the "Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level Cleared fifth of six monotherapy cohorts and second of four combination cohorts Kineta is actively exploring strategic alternatives to maximize value for all stakeholders Received $500,000 investment from an existing investor SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies in oncology

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level Cleared fifth of six monotherapy cohorts and second of four combination cohorts SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves

Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia. Nurix Therapeutics shares jumped 12.1% to $17.01 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) rose 89.4% to $6.61 in pre-market trading after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity. Interactive Strength Inc. (NASDAQ:TR

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by

Gainers Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. Can Fite Biofarma (AMEX:

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million. Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million. American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million. Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million. Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The marke

Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million. Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million. Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million. CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The marke

Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 82.9% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 39.58% to $0.16. The market value of their outstanding shares is at $10.2 million. The company's, Q1 earnings came out yesterday. Genetic Technologies (NASDAQ:GENE) stock rose 34.88% to $2.9. The company's market cap stands at $9.3 million. Surmodics (NASDAQ:SRDX) stock increased by 17.92% to $41.39. The market value of their outstanding shares is at $590.2 million. Ikena Oncology (NASDAQ:IKNA) stock increased by 17.33% to $1.56. The market value of their

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose levelCleared fifth of six monotherapy cohorts and second of four combination cohortsKineta is actively exploring strategic alternatives to maximize value for all stakeholdersReceived $500,000 investment from an existing investor